T
Tove Tuntland
Researcher at Genomics Institute of the Novartis Research Foundation
Publications - 50
Citations - 3804
Tove Tuntland is an academic researcher from Genomics Institute of the Novartis Research Foundation. The author has contributed to research in topics: In vivo & Cathepsin S. The author has an hindex of 29, co-authored 50 publications receiving 3335 citations. Previous affiliations of Tove Tuntland include University of Washington & University of Oslo.
Papers
More filters
Journal ArticleDOI
Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje,Wei Pei,Bei Chen,Wenshuo Lu,Tetsuo Uno,Jin Yunho,Tao Jiang,Sungjoon Kim,Nanxin Li,Markus Warmuth,Yelena Sarkisova,Frank Sun,Auzon Steffy,AnneMarie Culazzo Pferdekamper,Allen G. Li,Sean B. Joseph,Young Kim,Bo Liu,Tove Tuntland,Xiaoming Cui,Nathanael S. Gray,Ruo Steensma,Yongqin Wan,Jiqing Jiang,Chopiuk Greg,Jie Li,W. Perry Gordon,Wendy Richmond,Kevin Johnson,Jonathan Chang,Todd Groessl,You-Qun He,Andrew Phimister,Alex Aycinena,Christian C. Lee,Badry Bursulaya,Donald S. Karanewsky,H. Martin Seidel,Jennifer L. Harris,Pierre-Yves Michellys +39 more
TL;DR: In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684).
Journal ArticleDOI
Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery
Stephan Meister,David Plouffe,Kelli Kuhen,Ghislain M. C. Bonamy,Tao Wu,S. Whitney Barnes,Selina Bopp,Rachel Borboa,A. Taylor Bright,A. Taylor Bright,Jianwei Che,Steve Cohen,Neekesh V. Dharia,Kerstin Gagaring,Montip Gettayacamin,Perry Gordon,Todd Groessl,Nobutaka Kato,Marcus C. S. Lee,Case W. McNamara,David A. Fidock,Advait Nagle,Tae-gyu Nam,Wendy Richmond,Jason Roland,Matthias Rottmann,Matthias Rottmann,Bin Zhou,Patrick Froissard,Patrick Froissard,Richard Glynne,Dominique Mazier,Dominique Mazier,Jetsumon Sattabongkot,Peter G. Schultz,Tove Tuntland,John R. Walker,Yingyao Zhou,Arnab K. Chatterjee,Thierry T. Diagana,Elizabeth A. Winzeler,Elizabeth A. Winzeler +41 more
TL;DR: An imidazolopiperazine scaffold series was identified that was highly enriched among compounds active against Plasmodium liver stages and shows potent in vivo blood-stage therapeutic activity.
Journal ArticleDOI
Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
Tao Jiang,Kelli Kuhen,Karen Wolff,Hong Yin,Kimberly Bieza,Jeremy S. Caldwell,Badry Bursulaya,Tove Tuntland,Kanyin Zhang,Donald S. Karanewsky,Yun He +10 more
TL;DR: A series of heterocycle-containing oxindoles was synthesized and their HIV antiviral activities were assessed, finding some exhibited potent inhibitory activities against both wild-type virus and a number of drug-resistant mutant viruses.
Journal ArticleDOI
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
Shilpi Khare,Advait Nagle,Agnes Biggart,Yin H. Lai,Fang Liang,Lauren C. Davis,S. Whitney Barnes,Casey J. N. Mathison,Elmarie Myburgh,Elmarie Myburgh,Mu-Yun Gao,J. Robert Gillespie,Xianzhong Liu,Jocelyn Tan,Monique Stinson,Ianne C. Rivera,Jaime Ballard,Vince Yeh,Todd Groessl,Glenn C. Federe,Hazel X. Y. Koh,John D. Venable,Badry Bursulaya,Michael Shapiro,Pranab Mishra,Glen Spraggon,Ansgar Brock,Jeremy C. Mottram,Jeremy C. Mottram,Frederick S. Buckner,Srinivasa P. S. Rao,Ben G. Wen,John R. Walker,Tove Tuntland,Valentina Molteni,Richard Glynne,Frantisek Supek +36 more
TL;DR: A selective inhibitor of the kinetoplastid proteasome (GNF6702) with unprecedented in vivo efficacy, which cleared parasites from mice in all three models of infection, underscores the possibility of developing a single class of drugs for these neglected diseases.
Journal ArticleDOI
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
Shifeng Pan,Xu Wu,Jiqing Jiang,Wenqi Gao,Yongqin Wan,Dai Cheng,Dong Han,Jun Liu,Nathan P. Englund,Yan Wang,Stefan Peukert,Karen Miller-Moslin,Jing Yuan,Ribo Guo,Melissa Matsumoto,Anthony Vattay,Yun Jiang,Jeffrey Tsao,Fangxian Sun,AnneMarie Culazzo Pferdekamper,Stephanie Kay Dodd,Tove Tuntland,Wieslawa Maniara,Joseph Kelleher,Yung-mae Yao,Markus Warmuth,Juliet Williams,Marion Dorsch +27 more
TL;DR: Structural-activity relationship studies led to the discovery of a potent and specific Smoothened antagonist N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl- 3-carboxamide (5m, NVP-LDE225), which is currently in clinical development.